Royalty Pharma Plc
(NASDAQ : RPRX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. -0.25%40.000.9%$1281.75m
JNJJohnson & Johnson 0.14%170.190.7%$1253.43m
MRKMerck & Co., Inc. -0.60%78.220.7%$926.88m
ABBVAbbVie, Inc. -0.07%116.521.9%$721.02m
BMYBristol-Myers Squibb Co. -0.31%64.841.0%$719.56m
LLYEli Lilly & Co. 0.75%196.401.1%$573.53m
AZNAstraZeneca Plc 0.29%55.211.2%$531.67m
BTXBrooklyn ImmunoTherapeutics, Inc. -7.43%21.6912.8%$256.18m
GSKGlaxoSmithKline Plc 1.11%39.090.2%$191.43m
NVSNovartis AG 0.68%89.000.2%$173.64m
VTRSViatris, Inc. 0.44%16.000.0%$168.43m
CVACCureVac NV 7.47%109.990.0%$159.75m
NVONovo Nordisk A/S 0.28%79.110.1%$72.19m
SNYSanofi 0.38%52.740.2%$71.76m
ATNXAthenex, Inc. 3.25%5.080.0%$62.70m

Company Profile

Royalty Pharma Plc provides drug development services. The firm operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.